Now available on iOS and Android, Level One helps newly diagnosed Type 1 Diabetics and their caregivers master insulin management…
Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 – Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining…
Ingelheim, Germany, Oxford and Belfast, UK, April 29, 2025 – Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining…
LONDON, April 28, 2025 /PRNewswire/ -- Social tournament platform Papaya, which launched in the UK in January, has partnered with US-based…
MOTHERWELL, Scotland, April 23, 2025 /PRNewswire/ -- A patient who was previously classified as legally blind has regained over 50%…
MOTHERWELL, Scotland, April 23, 2025 /PRNewswire/ -- A patient who was previously classified as legally blind has regained over 50%…
MANCHESTER, England, April 17, 2025 /PRNewswire/ -- Monument Therapeutics, a precision-neuroscience company focused on the development of innovative treatments for…
Milestone Paves the Way for Commercialization, Unlocks New Research PotentialNEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation…
-- Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate --…
Enters into Agreement with Bradley L. Radoff and Michael TorokBOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq:…